AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 166 min read$IRD

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics (IRD) received FDA approval for phentolamine ophthalmic solution 0.75% to treat presbyopia, an age-related vision condition. The approval follows positive Phase 3 trial results and triggers a milestone payment. Viatris holds U.S. commercialization rights. The drug is marketed as RYZUMVI, with presbyopia as a new indication.

Original reporting
globenewswire.com
Published Oct 16, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 4:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia — source image
Source · globenewswire.com
Decision brief

The 30-second read

$IRDBullishMed
01

Why it matters

The FDA label expansion is supported by positive pivotal Phase 3 VEGA-2 and VEGA-3 results and is expected to trigger a milestone payment to Opus Genetics, improving the commercialization outlook for the product in the US.

02

Market read

Traders may reassess IRD’s regulatory execution and near-term cash-flow catalysts tied to the presbyopia approval milestone.

03

What to watch

The press release does not quantify expected sales ramp, pricing, or the size/timing of the milestone payment, which could limit how far the stock can re-rate without follow-on financial guidance.

Relevance 9/10Novelty 9/10Timing: today’s FDA approval headline, after-hours/close depending on local market timing

Background

Opus Genetics announced FDA approval of a supplemental NDA for phentolamine ophthalmic solution 0.75% (marketed as RYZUMVI) to include presbyopia in adults.

Company-level read

Ticker impact

$IRDBullishHigh confidence
Context

Opus Genetics (IRD) received FDA approval of an sNDA expanding phentolamine ophthalmic solution 0.75% to treat presbyopia in adults.

Expected impact

Likely positive repricing as investors price in incremental revenue potential and the disclosed milestone payment trigger.

Evidence & confidence

The article is a first-report FDA approval for IRD’s supplemental application, supported by pivotal Phase 3 VEGA-2/VEGA-3 results, and it explicitly states a presbyopia approval will trigger a milestone payment to Opus Genetics.

Market effects

Sector

Adds incremental validation for ophthalmic pharmacology and for Opus’s ability to execute regulatory milestones beyond gene therapy.

Regional

Limited, as the event is US FDA label expansion for a specific product.

Global

Moderate, since the licensing agreement is described as global and the US commercialization rights are central to near-term economics.

Counterpoint

What could challenge this read

The approval is for an ophthalmic indication expansion of an already-marketed product, so upside may be capped versus a brand-new asset launch.

Key entities

  • company
    Opus Genetics, Inc.

    Clinical-stage biopharmaceutical company; subject of the FDA supplemental approval announcement.

  • company
    Viatris Inc.

    Licensing partner with exclusive US commercialization rights for phentolamine ophthalmic solution 0.75%.

  • regulator
    U.S. Food and Drug Administration (FDA)

    Approved the supplemental NDA expanding the indication to presbyopia in adults.

Read at source← All news

StoryFDA expands RYZUMVI approval to treat presbyopia in adults

Also covered by

4 outlets

Related articles

OCT 21
$IRDMedAI 8/10

Opus Genetics receives FDA clearance for RDH12-LCA gene therapy

Opus Genetics (NASDAQ:IRD) received FDA clearance for its gene therapy OPGx-RDH12, targeting RDH12-associated Leber congenital amaurosis. The company plans to start a Phase 1/2 trial this quarter. The therapy aims to restore retinal function in a rare inherited disease affecting 30,900 people globally. Opus Genetics collaborates with the Global RDH12 Alliance, which committed up to $1.6 million for development.

investing.com2 min
OCT 16
$IRDMedAI 8/10

Opus Genetics (IRD) Gains FDA Approval for Ryzumvi Label Expansi

Opus Genetics (IRD) received FDA approval to expand Ryzumvi's use to adults with presbyopia, a milestone that triggers a payment from partner Viatris (VTRS). IRD's P/S ratio is 29.84, far above its historical median, reflecting high growth expectations despite its unprofitability. The company's GF Score is 21, indicating financial and operational challenges, and insiders have sold $19.3M in shares over the past year.

gurufocus.com5 min
OCT 16
$IRDMedAI 9/10

Opus Genetics (IRD) Gains FDA Approval for Phentolamine Ophthalm

Opus Genetics (IRD) received FDA approval for its phentolamine ophthalmic solution, triggering a licensing agreement payment. The company trades at a high P/S ratio of 30.33, reflecting growth expectations despite financial challenges. Insider activity shows significant selling. The FDA approval follows successful clinical trials for presbyopia treatment.

gurufocus.com6 min
OCT 16
$IRDHighAI 8/10

FDA approves Opus Genetics’ eye drops for presbyopia treatment

Opus Genetics (IRD) received FDA approval for RYZUMVI, a drug to treat presbyopia in adults. The approval expands the drug's use beyond its initial indication. The company has a licensing agreement with Viatris (VTRS), which holds U.S. commercialization rights. The FDA approval triggers a milestone payment to Opus Genetics, though the amount was not disclosed.

investing.com2 min